Front & Back Matter.
- Published in:
- Inflammatory Intestinal Diseases, 2022, v. 7, n. 3/4, p. 1, doi. 10.1159/000530324
- Publication type:
- Article
Works matching IS 22969403 AND DT 2022 AND VI 7 AND IP 3/4
Results: 7
1
2
Contents Vol. 7, 2022.
- Published in:
- Inflammatory Intestinal Diseases, 2022, v. 7, n. 3/4, p. I, doi. 10.1159/000530064
- Publication type:
- Article
3
The Impact of Concomitant Ulcerative Colitis on the Clinical Course in Patients with Primary Sclerosing Cholangitis: An Investigation Using a Nationwide Database in Japan.
- Published in:
- Inflammatory Intestinal Diseases, 2022, v. 7, n. 3/4, p. 147, doi. 10.1159/000529338
- By:
- Publication type:
- Article
4
A Regional Survey of Awareness of Inflammatory Bowel Disease among the Saudi Population.
- Published in:
- Inflammatory Intestinal Diseases, 2022, v. 7, n. 3/4, p. 139, doi. 10.1159/000529318
- By:
- Publication type:
- Article
5
Molecular Basis of Intestinal Fibrosis in Inflammatory Bowel Disease.
- Published in:
- Inflammatory Intestinal Diseases, 2022, v. 7, n. 3/4, p. 119, doi. 10.1159/000528312
- By:
- Publication type:
- Article
6
Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan.
- Published in:
- Inflammatory Intestinal Diseases, 2022, v. 7, n. 3/4, p. 128, doi. 10.1159/000528185
- By:
- Publication type:
- Article
7
Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial.
- Published in:
- Inflammatory Intestinal Diseases, 2022, v. 7, n. 3/4, p. 155, doi. 10.1159/000526264
- By:
- Publication type:
- Article